Physician profile
Shruti Desai
NPI 1588140636
$2,494.66
in general payments reported to CMS, 2019-2025
14 companies · $692 in 2025
The $692 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $30.40 · 2021: $294 · 2022: $262 · 2023: $151 · 2024: $595 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $592.50 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Sun Pharmaceutical Industries INC. | $417.81 | 2021-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $370.43 | 2021-2025 | Acuvue |
| Glaukos Corporation | $260.57 | 2025 | Idosetr |
| Bausch & Lomb Americas INC. | $248.74 | 2024-2025 | Infuse, Miebo, Xiidra |
| Biotissue Holdings INC. | $232.26 | 2024 | |
| Alcon Vision LLC | $131.34 | 2021 | |
| Shire North American Group INC | $106.68 | 2019 | |
| Abbvie INC. | $51.00 | 2023 | Alphagan P, Lumigan, Restasis Multidose |
| Novartis Pharmaceuticals Corporation | $21.36 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.27 | 2019 | |
| Spark Therapeutics, INC. | $17.18 | 2019 | |
| Optos, INC. | $12.53 | 2021 | |
| Optovue, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.